Soluble ST2 and galectin-3 in pediatric patients without heart failure

Clinical Biochemistry

Volumn 48, Issue 18, 2015, Pages 1337-1340

  Meeusen, Jeffrey W ^a   Johnson, Jonathan N ^a   Gray, Amber ^a   Wendt, Patricia ^a   Jefferies, John L ^b   Jaffe, Allan S ^a   Donato, Leslie J ^a   Saenger, Amy K ^a  

^a MAYO CLINIC   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Cardiomyopathy; Natriuretic peptides; Reference range

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3; PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BIOCHEMICAL ANALYSIS; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SCHOOL CHILD; AGE; BLOOD; CARDIOMYOPATHIES; COHORT ANALYSIS; GENE EXPRESSION; GENETICS; SEX DIFFERENCE;

ADOLESCENT; AGE FACTORS; BIOMARKERS; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTIN 3; GENE EXPRESSION; HEART FAILURE; HUMANS; MALE; RECEPTORS, CELL SURFACE; REFERENCE VALUES; SEX FACTORS;

EID: 84949093186     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.08.007     Document Type: Article

References (15)

1. Price J.F., Thomas A.K., Grenier M., Eidem B.W., O'Brian Smith E., Denfield S.W., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006, 114:1063-1069.
2. Mir T.S., Haun C., Lilje C., Laer S., Weil J. Utility of n-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery. Pediatr. Cardiol. 2006, 27:209-216.
3. Kirk R., Dipchand A., Rosenthal D. Family therapy outcome research: knowns and unknowns. ISHLT guidelines for the management of pediatric heart failure 2014, ISHLT monograph series, Birmingham, AL. J. Kirklin (Ed.).
4. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 128:1810-1852.
5. Tang W.H., Shrestha K., Shao Z., Borowski A.G., Troughton R.W., Thomas J.D., et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 2011, 108:385-390.
6. Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 2008, 52:1458-1465.
7. de Boer R.A., Lok D.J., Jaarsma T., van der Meer P., Voors A.A., Hillege H.L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 2011, 43:60-68.
8. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., Casas T., Garrido I.P., Bonaque J.C., et al. Soluble ST2, high-sensitivity troponin t- and n-terminal pro-b-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur. J. Heart Fail. 2011, 13:718-725.
9. Pascual-Figal D.A., Garrido I.P., Blanco R., Minguela A., Lax A., Ordonez-Llanos J., et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann. Thorac. Surg. 2011, 92:2118-2124.
10. Coglianese E.E., Larson M.G., Vasan R.S., Ho J.E., Ghorbani A., McCabe E.L., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin. Chem. 2012, 58:1673-1681.
11. Dieplinger B., Januzzi J.L., Steinmair M., Gabriel C., Poelz W., Haltmayer M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the presage ST2 assay. Clin. Chim. Acta 2009, 409:33-40.
12. Lu J., Snider J.V., Grenache D.G. Establishment of reference intervals for soluble ST2 from a United States population. Clin. Chim. Acta 2010, 411:1825-1826.
13. Christenson R.H., Duh S.H., Wu A.H., Smith A., Abel G., deFilippi C.R., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin. Biochem. 2010, 43:683-690.
14. La'ulu S.L., Apple F.S., Murakami M.M., Ler R., Roberts W.L., Straseski J.A. Performance characteristics of the architect galectin-3 assay. Clin. Biochem. 2013, 46:119-122.
15. Mueller T., Leitner I., Egger M., Haltmayer M., Dieplinger B. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin. Chim. Acta 2015, 445:155-160.